A larger sample size, assessment of not only total but also monomeric prolactin, and a small (25–31%) proportion of individuals with prolactin-secreting tumors (only microprolactinomas) may account for the inconsistency with previous findings. This evidence concerns the gene PRL and Microprolactinoma.